Switch theme
Sign up to access all valuation multiples
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
2017
87
LTM Revenue $33.2M
LTM EBITDA n/a
-$29.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HOOKIPA Pharma has a last 12-month revenue of $33.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, HOOKIPA Pharma achieved revenue of $43.9M and an EBITDA of -$40.9M.
HOOKIPA Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HOOKIPA Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $20.1M | $43.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$77.3M | -$40.9M | XXX | XXX | XXX |
| EBITDA Margin | -384% | -93% | XXX | XXX | XXX |
| Net Profit | -$64.9M | -$81.6M | XXX | XXX | XXX |
| Net Margin | -322% | -186% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, HOOKIPA Pharma's stock price is $1.
HOOKIPA Pharma has current market cap of $9.2M, and EV of -$29.6M.
See HOOKIPA Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$29.6M | $9.2M | XXX | XXX | XXX | XXX | $-3.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, HOOKIPA Pharma has market cap of $9.2M and EV of -$29.6M.
HOOKIPA Pharma's trades at -0.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate HOOKIPA Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for HOOKIPA Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$29.6M | XXX | XXX | XXX |
| EV/Revenue | -0.7x | XXX | XXX | XXX |
| EV/EBITDA | 0.7x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHOOKIPA Pharma's NTM/LTM revenue growth is -85%
HOOKIPA Pharma's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, HOOKIPA Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate HOOKIPA Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for HOOKIPA Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 118% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -93% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -178% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 156% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 185% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HOOKIPA Pharma acquired XXX companies to date.
Last acquisition by HOOKIPA Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . HOOKIPA Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was HOOKIPA Pharma founded? | HOOKIPA Pharma was founded in 2017. |
| Where is HOOKIPA Pharma headquartered? | HOOKIPA Pharma is headquartered in United States of America. |
| How many employees does HOOKIPA Pharma have? | As of today, HOOKIPA Pharma has 87 employees. |
| Who is the CEO of HOOKIPA Pharma? | HOOKIPA Pharma's CEO is Dr. Malte Peters, M.D.. |
| Is HOOKIPA Pharma publicy listed? | Yes, HOOKIPA Pharma is a public company listed on NAS. |
| What is the stock symbol of HOOKIPA Pharma? | HOOKIPA Pharma trades under HOOK ticker. |
| When did HOOKIPA Pharma go public? | HOOKIPA Pharma went public in 2019. |
| Who are competitors of HOOKIPA Pharma? | Similar companies to HOOKIPA Pharma include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of HOOKIPA Pharma? | HOOKIPA Pharma's current market cap is $9.2M |
| What is the current revenue of HOOKIPA Pharma? | HOOKIPA Pharma's last 12-month revenue is $33.2M. |
| What is the current EV/Revenue multiple of HOOKIPA Pharma? | Current revenue multiple of HOOKIPA Pharma is -0.9x. |
| What is the current revenue growth of HOOKIPA Pharma? | HOOKIPA Pharma revenue growth between 2023 and 2024 was 118%. |
| Is HOOKIPA Pharma profitable? | Yes, HOOKIPA Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
